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Adenosine-treated patients had a
a similar MACE-free survival curve
event(s).To the Editor: In about 30% to 50% of patients with ST-segment
elevation myocardial infarction (STEMI) treated by primary
percutaneous coronary intervention (PCI), microvascular obstruc-
tion (MVO) reduces the beneﬁcial effects of a successful recanali-
zation of the infarct-related artery (1). The open-label, randomized,
placebo-controlled evaluation of intracoronary adenosine or nitro-
prusside after thrombus aspiration during primary percutaneous
coronary intervention for the prevention ofmicrovascular obstruction
in acute myocardial infarction (REOPEN-AMI [Intracoronary
Nitroprusside Versus Adenosine in Acute Myocardial Infarction]
study) showed that the intracoronary administration of a high dose
of adenosine, but not of a high dose of nitroprusside, given selectively
into the infarct-related artery after thrombus aspiration, improved
MVO, as assessed by ST-segment resolution (2). We present here
left ventricular remodeling data and the 1-year clinical outcomes of
patients enrolled in the REOPEN-AMI study (2).
Six hospitals in Italy enrolled patients from September 2008 to
September 2011. Details of the study design have been previously
reported (2). Brieﬂy, a total of 240 STEMI patients presenting
with Thrombolysis In Myocardial Infarction (TIMI) ﬂow grade
0/1 were randomly allocated 1:1:1 to receive adenosine (120 mg as
fast bolus followed by 2 mg given in 33 ml of saline over 2 min as
slow bolus, n ¼ 80), nitroprusside (60 mg as fast bolus followed byal Kaplan-Meier Curves According to Treatment G
better MACE-free survival curve when compared with thos
when compared with those treated by placebo (log-rank p100 mg given in 33 ml of 5% glucose over 2 min as slow bolus,
n ¼ 80), or saline (2 ml of heparinized saline as fast bolus followed
by 33 ml of heparinized saline given over 2 min as slow bolus,n ¼
80) distal to the occluded site after thrombus aspiration. Of note,
among included patients, 7 patients undergoing rescue PCI were
also enrolled (n ¼ 2 in the adenosine group, n ¼ 3 in the nitro-
prusside group, and n ¼ 2 in the saline group).
The primary endpointwas the incidence of ST-segment resolution
>70% on surface electrocardiogram at 90 min after PCI. In this
study, we report pre-speciﬁed secondary endpoint data about the
major adverse cardiac event (MACE) rate at 1-year clinical follow-up
(FU) as a composite of cardiac death, myocardial infarction, target
lesion revascularization, and heart failure requiring hospitalization
and the rate of left ventricular remodeling at 1-year echocardio-
graphic FU, deﬁned as an increase in end-diastolic volume 20%,
based on repeated measurements in individual patients and on the
upper 95% conﬁdence limit of the intraobserver variability (3).
Data distribution was assessed by the Kolmogorov-Smirnov test.
Variables that did not follow a normal distribution were expressed
as medians and interquartile ranges, whereas other continuous
variables were expressed as mean  SD; categorical variables were
expressed as proportions. Comparison between categorical variables
was done using the chi-square test or Fisher’s exact test, asroups
e treated by placebo (log-rank p¼ 0.003), whereas nitroprusside-treated patients had
¼ 0.15). CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiac
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1455appropriate. The Student t-test or Mann-Whitney U test was used
for the comparison of continuous variables, as appropriate. Data
have been analyzed according to the intention-to-treat principle.
Two-sided tests were used, and a p value <0.025 (using the
Bonferroni adjustment, alpha level/number of comparison: 0.05/2)
was the statistical signiﬁcance level. MACE curves using the
Kaplan-Meier methods were produced for treatment group and
compared by the log-rank test. The software SPSS version 17.0
(SPSS Italia, Florence, Italy) was used for all statistical analyses.
One-year FU was complete in all but 5 of 240 patients (2 pa-
tients in the adenosine group, 1 patient in the nitroprusside group,
and 2 patients in the placebo group). As in the main study, de-
mographics, cardiovascular risk factors, ischemic times, Killip
classes and discharge therapy did not differ signiﬁcantly among
treatment groups (p ¼ NS, data not shown). Of note, compliance
with therapy at FU was nearly 90% for all drugs and was similar
among treatment groups (p ¼ NS). Baseline end-diastolic and end-
systolic left ventricular volumes were similar between adenosine-
treated patients (105  19 ml and 62  15 ml, respectively) or
nitroprusside-treated patients (107  21 ml and 64  16 ml,
respectively) and saline-treated patients (104  20 ml and 65  15
ml, respectively), p ¼ 0.59, p ¼ 0.42, p ¼ 0.48, p ¼ 0.68,
respectively), with no signiﬁcant differences between adenosine-
and nitroprusside-treated patients (p ¼ 0.57 and p ¼ 0.61,
respectively). However, at 1-year echocardiographic FU, the left
ventricular remodeling rate occurred less frequently in the
adenosine-treated patients as compared with the placebo-treated
patients (6% vs. 23%, p ¼ 0.006), whereas it was similar between
nitroprusside- and placebo-treated patients (18% vs. 23%,
p ¼ 0.43), and tended to be less frequent in the adenosine-treated
patients as compared with the nitroprusside-treated patients
(p ¼ 0.07). The MACE rate at 1-year FU was signiﬁcantly lower
in the adenosine group (2 deaths, 1 myocardial infarction, 6 target-
lesion revascularizations, 1 heart failure) as compared with the
placebo group (4 deaths, 5 myocardial infarctions, 7 target-lesion
revascularizations, 7 heart failures) (13% vs. 31%, p ¼ 0.01),
whereas it was similar between the nitroprusside (3 deaths, 4
myocardial infarctions, 7 target–lesion revascularizations, 3 heart
failures) and the placebo groups (21% vs. 31%, p ¼ 0.21) and
between the adenosine and the nitroprusside groups (p ¼ 0.21). Of
note, hospitalization for heart failure tended to occur less frequently
in the adenosine group as compared with the placebo group (1% vs.
9%, p ¼ 0.06). Kaplan-Meier curves for MACE-free survival ac-
cording to treatment allocation are shown in Figure 1.
In this study, we showed that high-dose intracoronary adenosine
administration in patients with STEMI undergoing primary PCI is
associated with improved clinical outcomes after 1 year, mainly because
of a reduction in hospitalization for heart failure and less left ventricular
negative remodeling (with a statistical power of 99% for adenosine vs.
saline and 95% for nitroprusside vs. saline). Because this effect was
borderline after 1 month (2), it suggests that the beneﬁcial effects of
adenosine on clinical outcomes need more time in order to be
demonstrated, as adenosine may have an impact on the rate of left
ventricular remodeling (4) after STEMI. The adenosine-related im-
provements of left ventricular remodeling and clinical outcome are
probably due to its effects on MVO and infarct size. Indeed, both re-
ductions ofMVOand infarct size have been related to improved clinical
outcome (1). Multiple cardioprotective effects of adenosine have been
reported, including its potent direct vasodilatory effect on the coronary
microcirculation, its anti-inﬂammatory properties against neutrophils,
and its ability to inhibit platelet aggregation, to stimulate angiogenesis,and to mimic ischemic pre-conditioning, thus probably accounting for
the beneﬁcial effects observed in this trial (5). In particular, on the basis
of these effects, left ventricular remodeling improvementmay be related
to a better healing process of a smaller infarct area in adenosine-treated
patients (suggested also by the smaller enzymatic infarct size observed in
the main study for adenosine-treated patients). This study is not pow-
ered, however, to demonstrate a mortality beneﬁt, thus further studies
should test larger populations for the impact of intracoronary adenosine





Catholic University of the Sacred Heart





From the Institute of Cardiology, Catholic University of the Sacred
Heart, Rome, Italy.
REFERENCES
1. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reﬂow in
humans. J Am Coll Cardiol 2009;54:281–92.
2. NiccoliG,Rigattieri S,DeVitaMR, et al.Open-label, randomized, placebo-
controlled evaluation of intracoronary adenosine or nitroprusside after
thrombus aspiration during primary percutaneous coronary intervention for
thepreventionofmicrovascular obstruction in acutemyocardial infarction: the
REOPEN-AMI study. J Am Coll Cardiol Intv 2013;6:580–9.
3. Bolognese L, Neskovic AN, Parodi G, et al. Left ventricular remodeling
after primary coronary angioplasty: patterns of left ventricular dilation
and long-term prognostic implications. Circulation 2002;106:2351–7.
4. Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular
dysfunction on left ventricular remodeling and long-term clinical outcome
after primary coronary angioplasty for acute myocardial infarction. Cir-
culation 2004;109:1121–6.
5. Safran N, Shneyvays V, Balas N, Jacobson KA, Nawrath H,
Shainberg A. Cardioprotective effects of adenosine A1 and A3 receptor
activation during hypoxia in isolated rat cardiac myocytes. Mol Cell





Catastrophic Insurance ClaimsTo the Editor: An accurate understanding of the incidence of car-
diovascular events in athletes is central to the development and
